VCEL - Vericel CorporationAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $20.68 | Open | $21.00 |
| Volume | 438.7K | Market Cap | 684.58M |
| Yield | Last Dividend |
| The Daily Biotech Pulse: J&J Pauses Coro... | 10/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12) 10X... | |
| P/E Ratio Insights for Vericel | 10/12/20 |
| In the current session, Vericel Inc. (NASDAQ: VCEL) is trading at $21.92, after a 0.46% gain. Over the past month, the stock increased ??? | |
| The Daily Biotech Pulse: Bristol-Myers S... | 10/07/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) 10X ... | |
| The Daily Biotech Pulse: Pfizer, BioNTec... | 10/06/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) 10X ... | |
| World Cell & Gene Therapy Markets, 2025 ... | 08/06/20 |
| DUBLIN--(BUSINESS WIRE)--The "Cell & Gene Therapy Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's of... | |
| Vericel (VCEL) Q2 2020 Earnings Call Tra... | 08/06/20 |
| VCEL earnings call for the period ending June 30, 2020. | |
| Vericel Reports Second Quarter 2020 Fina... | 08/05/20 |
| Product Revenues of $20.0 Million Reported for the Second Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE?... | |
| Vericel to Report Second-Quarter 2020 Fi... | 07/22/20 |
| CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and seve... | |
| Vericel Announces Preliminary Second Qua... | 07/09/20 |
| CAMBRIDGE, Mass., July 09, 2020 -- Vericel Corporation , a leader in advanced therapies for the sports medicine and severe burn care markets, today an... | |
| Vericel Announces Submission of Biologic... | 06/30/20 |
| CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced the submission of a Biologics License Applicati... | |
| Zacks.com featured highlights include: M... | 05/27/20 |
| Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories | |
| Regenerative Medicine Industry Outlook t... | 05/14/20 |
| DUBLIN, May 14, 2020 /PRNewswire/ -- The "Global Regenerative Medicine Market By Therapy (Cell-Based Immunotherapy & Cell Therapy, Gene Therapy, Other... | |
| The Week Ahead In Biotech: Smid-Cap Earn... | 05/03/20 |
| Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma nam... | |
| Should You Buy Vericel (VCEL) Ahead of E... | 02/24/20 |
| Vericel (VCEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. | |
| Vericel Analyst Projects Wound Care Prod... | 10/09/19 |
| Vericel Corp (NASDAQ: VCEL ), a commercial-stage company that specializes in advanced cell therapies for treating patients with knee cartilage defects... | |
| Vericel (VCEL) Presents At UBS Global He... | 05/23/19 |
| No summary available. | |
| Vericel (VCEL) Q1 2019 Earnings Call Tra... | 05/08/19 |
| VCEL earnings call for the period ending March 31, 2019. | |
| Vericel Corporation (VCEL) CEO Nick Cola... | 05/08/19 |
| No summary available. | |
| Vericel Corporation 2019 Q1 - Results - ... | 05/07/19 |
| No summary available. | |
| Vericel nabs North American rights to Me... | 05/07/19 |
| MediWound (MDWD) has out-licensed exclusive rights to debridement agent NexoBrid to Vericel (VCEL) in North America. Under the terms of the agreement,... | |
| Vericel EPS in-line, misses on revenue | 05/07/19 |
| No summary available. | |
| Will Vericel (VCEL) Report Negative Earn... | 04/30/19 |
| Vericel (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with t... | |
| Disney+ And Bank Majors Step Out (Stocks... | 04/07/19 |
| No summary available. | |
| Osiris Therapeutics: Elucidating The Ram... | 03/19/19 |
| No summary available. | |
| How To Increase Return And Control Marke... | 03/11/19 |
| No summary available. | |
| How To Increase Return And Control Marke... | 03/11/19 |
| No summary available. | |
| Cowen likes managed care firms in premar... | 02/28/19 |
| No summary available. | |
| Vericel Corporation (VCEL) CEO Nick Cola... | 02/26/19 |
| No summary available. | |
| Vericel up 13% on Q4 result | 02/26/19 |
| No summary available. | |
| Vericel beats by $0.07, beats on revenue | 02/26/19 |
| No summary available. | |
| Buy rating | 12:00 AM |
| BTIG maintains Buy rating and raises Price Target from $23.00 to $30.00 | |
| Buy rating | 10/15/20 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $22.00 to $26.00 | |
| Strong Buy rating | 10/12/20 |
| SVB Leerink maintains Outperform rating and raises Price Target from $20.00 to $30.00 | |
| Buy rating | 09/17/20 |
| Truist Securities initiates coverage with Buy rating and announces Price Target of $24.00 | |
| Date | 2020-08-05 (BMO) | Est. (EPS/Rev.) | ($0.21)/ 18.87M |
| Actual (EPS/Rev.) | $-0.18/ $20.01 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
